Stuart G Turville
Overview
Explore the profile of Stuart G Turville including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
1667
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mazigi O, Langley D, Henry J, Burnett D, Sobti M, Walker G, et al.
Proc Natl Acad Sci U S A
. 2025 Jan;
122(1):e2417544121.
PMID: 39746041
The emergence of SARS-CoV-2 variants of concern (VOCs) has greatly diminished the neutralizing activity of previously FDA-approved monoclonal antibodies (mAbs), including that of antibody cocktails and of first-generation broadly neutralizing...
2.
Shrestha L, Tungatt K, Aggarwal A, Stubis A, Fewings N, Fichter C, et al.
EBioMedicine
. 2024 Nov;
110:105461.
PMID: 39612651
Background: Current literature informs us that bivalent vaccines will generate a broader serum neutralizing antibody response to multiple SARS-CoV-2 variants, but studies on how this breadth relates to the memory...
3.
Akerman A, Fichter C, Milogiannakis V, Esneau C, Silva M, Ison T, et al.
EBioMedicine
. 2024 Nov;
110:105415.
PMID: 39549677
Background: Continued phenotyping and ongoing molecular epidemiology are important in current and future monitoring of emerging SARS-CoV-2 lineages. Herein we developed pragmatic strategies to track the emergence, spread and phenotype...
4.
Zhang L, Dopfer-Jablonka A, Cossmann A, Stankov M, Graichen L, Moldenhauer A, et al.
iScience
. 2024 May;
27(6):109904.
PMID: 38812550
In July/August 2023, the highly mutated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) BA.2.86 lineage emerged and its descendant JN.1 is on track to become the dominant SARS-CoV-2 lineage globally....
5.
Phetsouphanh C, Jacka B, Ballouz S, Jackson K, Wilson D, Manandhar B, et al.
Nat Commun
. 2024 Apr;
15(1):3315.
PMID: 38632311
This study investigates the humoral and cellular immune responses and health-related quality of life measures in individuals with mild to moderate long COVID (LC) compared to age and gender matched...
6.
Faysal K, Walsh J, Renner N, Marquez C, Shah V, Tuckwell A, et al.
Elife
. 2024 Feb;
13.
PMID: 38347802
The HIV-1 capsid has emerged as a tractable target for antiretroviral therapy. Lenacapavir, developed by Gilead Sciences, is the first capsid-targeting drug approved for medical use. Here, we investigate the...
7.
Girkin J, Bryant N, Loo S, Hsu A, Kanwal A, Williams T, et al.
Am J Respir Cell Mol Biol
. 2023 Aug;
69(6):614-622.
PMID: 37603788
Respiratory virus infections initiate and transmit from the upper respiratory tract (URT). Coronaviruses, including OC43, are a major cause of respiratory infection and disease. Failure to mount an effective antiviral...
8.
Lee W, Tan H, Reynaldi A, Esterbauer R, Koutsakos M, Nguyen J, et al.
Sci Adv
. 2023 Jul;
9(29):eadg5301.
PMID: 37478181
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection of vaccinated individuals is increasingly common with the circulation of highly immune evasive and transmissible Omicron variants. Here, we report the...
9.
Pillay A, Yeola A, Tea F, Denkova M, Houston S, Burrell R, et al.
J Clin Immunol
. 2023 Jul;
43(8):1706-1723.
PMID: 37405544
Although a more efficient adaptive humoral immune response has been proposed to underlie the usually favorable outcome of pediatric COVID-19, the breadth of viral and vaccine cross-reactivity toward the ever-mutating...
10.
Thijssen V, Hurdiss D, Debski-Antoniak O, Spence M, Franck C, Norman A, et al.
Proc Natl Acad Sci U S A
. 2023 Jun;
120(26):e2303292120.
PMID: 37339194
The ongoing COVID-19 pandemic has had great societal and health consequences. Despite the availability of vaccines, infection rates remain high due to immune evasive Omicron sublineages. Broad-spectrum antivirals are needed...